history of glp-1 agonists Market Report 2025-2033, By Product, Molecule, and Geo The metabolic health revolution has

Learn what to expect from each type of medication and how to manage symptoms for better results.

However, the coexistence of micro and macrovascular disease is associated with the highest cardiovascular risks which highlights the importance that pharmacological treatment of type 2 diabetes mellitus provides not only glycemic control, but also cardiovascular safety

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

are the major companies operating in this market.

This product is not intended to diagnose, treat, cure, or prevent any disease